Finch Therapeutics Group

Finch Therapeutics is a microbiome-focused biotechnology company that developed a proprietary platform to create a new class of orally administered biological drugs. The company's Human-First Discovery platform utilizes machine learning to identify microbial communities that drive clinical responses in patients, bypassing traditional animal models. Their lead candidate, CP101, was designed as a complete microbiome therapeutic for the prevention of recurrent Clostridioides difficile infection and reached Phase 3 clinical trials. In early 2023, the company underwent a significant strategic restructuring, halting its clinical development programs to focus on realizing the value of its intellectual property and exploring strategic alternatives. Finch remains a pioneer in the field of live biotherapeutic products, particularly in the standardization of donor-derived microbial therapies.